Angiogenic factors and acute-phase proteins in serum samples of preeclampsia and HELLP patients: A matched-pair analysis

Journal of Maternal-Fetal and Neonatal Medicine

Volumn 26, Issue 3, 2013, Pages 263-269

  Reimer, Toralf ^a   Rohrmann, Henrike ^a   Stubert, Johannes ^a   Pecks, Ulrich ^b   Glocker, Michael O ^a   Richter, Dagmar Ulrike ^a   Gerber, Bernd ^a  

^a UNIVERSITY OF ROSTOCK   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

Acute phase protein; Endoglin; Gestational hypertensive disorder; PlGF; Serum marker; SFlt 1

Indexed keywords

AMYLOID A PROTEIN; C REACTIVE PROTEIN; ENDOGLIN; PLACENTAL GROWTH FACTOR; SOLUBLE FMS LIKE TYROSINE KINASE 1 RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; HELLP SYNDROME; HUMAN; IMMUNOASSAY; LIMIT OF DETECTION; MAJOR CLINICAL STUDY; MOLECULAR DIAGNOSIS; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT;

ACUTE-PHASE PROTEINS; ADULT; ANGIOGENESIS INDUCING AGENTS; ANTIGENS, CD; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; FEMALE; HELLP SYNDROME; HUMANS; INFANT, NEWBORN; MATCHED-PAIR ANALYSIS; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; RECEPTORS, CELL SURFACE; YOUNG ADULT;

EID: 84872359869     PISSN: 14767058     EISSN: 14764954     Source Type: Journal    
DOI: 10.3109/14767058.2012.733747     Document Type: Article

References (30)

1. Steegers EA, von Dadelszen P, Duvekot JJ, Pijnenborg R. Pre-eclampsia. Lancet 2010;376:631-644.
2. Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130-137.
3. Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, Pape J, et al. An automated method for the determination of the sFlt-1/ PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1-161.e11.
4. Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, Sibai BM, et al.; CPEP Study Group. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992-1005. (Pubitemid 44343543)
5. Levine RJ, Maynard SE, Qian C, Lim KH, England LJ, Yu KF, Schisterman EF, et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004;350:672-683. (Pubitemid 38364626)
6. Haram K, Svendsen E, Abildgaard U. The HELLP syndrome: clinical issues and management. A Review. BMC Pregnancy Childbirth 2009;9:8.
7. Sibai BM. Diagnosis, controversies, and management of the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 2004;103:981-991. (Pubitemid 40459001)
8. Sep S, Verbeek J, Koek G, Smits L, Spaanderman M, Peeters L. Clinical differences between early-onset HELLP syndrome and early-onset preeclampsia during pregnancy and at least 6 months postpartum. Am J Obstet Gynecol 2010;202:271.e1-271.e5.
9. Várkonyi T, Nagy B, Füle T, Tarca AL, Karászi K, Schönléber J, Hupuczi P, et al. Microarray profiling reveals that placental transcriptomes of early-onset HELLP syndrome and preeclampsia are similar. Placenta 2011;32 Suppl:S21-S29.
10. Heitner JC, Koy C, Kreutzer M, Gerber B, Reimer T, Glocker MO. Differentiation of HELLP patients from healthy pregnant women by proteome analysis-on the way towards a clinical marker set. J Chromatogr B Analyt Technol Biomed Life Sci 2006;840:10-19. (Pubitemid 44108804)
11. Koy C, Heitner JC, Woisch R, Kreutzer M, Serrano-Fernandez P, Gohlke R, Reimer T, Glocker MO. Cryodetector mass spectrometry profiling of plasma samples for HELLP diagnosis: an exploratory study. Proteomics 2005;5:3079-3087. (Pubitemid 41176474)
12. Pecks U, Seidenspinner F, Röwer C, Reimer T, Rath W, Glocker MO. Multifactorial analysis of affinity-mass spectrometry data from serum protein samples: a strategy to distinguish patients with preeclampsia from matching control individuals. J Am Soc Mass Spectrom 2010;21:1699-1711.
13. Maynard SE, Min JY, Merchan J, Lim KH, Li J, Mondal S, Libermann TA, et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003;111:649-658. (Pubitemid 36278583)
14. Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. N Engl J Med 2006;355:1056-1058. (Pubitemid 44343551)
15. Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim YM, Bdolah Y, et al. Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med 2006;12:642-649. (Pubitemid 43865232)
16. Young B, Levine RJ, Salahuddin S, Qian C, Lim KH, Karumanchi SA, Rana S. The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med 2010;23:366-370.
17. Hertig A, Fort J, Lefevre G, Chabbert-Buffet N, Uzan M, Rondeau E, Rozenberg P. Soluble endoglin in preeclamptic patients with or without HELLP syndrome. Am J Obstet Gynecol 2010;202:594.e1-594.e4.
18. Buimer M, Keijser R, Jebbink JM, Wehkamp D, van Kampen AH, Boer K, van der Post JA, Ris-Stalpers C. Seven placental transcripts characterize HELLP-syndrome. Placenta 2008;29:444-453.
19. Moore Simas TA, Crawford SL, Solitro MJ, Frost SC, Meyer BA, Maynard SE. Angiogenic factors for the prediction of preeclampsia in high-risk women. Am J Obstet Gynecol 2007;197:244.e1-244.e8.
20. Stepan H, Unversucht A, Wessel N, Faber R. Predictive value of maternal angiogenic factors in second trimester pregnancies with abnormal uterine perfusion. Hypertension 2007;49:818-824. (Pubitemid 351664216)
21. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999;340:448-454. (Pubitemid 29084777)
22. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991;146:3032-3037.
23. Malle E, De Beer FC. Human serum amyloid A (SAA) protein: a prominent acute-phase reactant for clinical practice. Eur J Clin Invest 1996;26:427-435. (Pubitemid 26226404)
24. Kovacevic A, Hammer A, Sundl M, Pfister B, Hrzenjak A, Ray A, Ray BK, et al. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett 2006;580:161-167. (Pubitemid 43005330)
25. Zhao Y, He X, Shi X, Huang C, Liu J, Zhou S, Heng CK. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm Res 2010;59:323-334.
26. Baumann H, Richards C, Gauldie J. Interaction among hepatocytestimulating factors, interleukin 1, and glucocorticoids for regulation of acute phase plasma proteins in human hepatoma (HepG2) cells. J Immunol 1987;139:4122-4128. (Pubitemid 18013708)
27. Hua S, Song C, Geczy CL, Freedman SB, Witting PK. A role for acutephase serum amyloid A and high-density lipoprotein in oxidative stress, endothelial dysfunction and atherosclerosis. Redox Rep 2009;14:187-196.
28. Maier W, Altwegg LA, Corti R, Gay S, Hersberger M, Maly FE, Sütsch G, et al. Inflammatory markers at the site of ruptured plaque in acute myocardial infarction: locally increased interleukin-6 and serum amyloid A but decreased C-reactive protein. Circulation 2005;111:1355-1361. (Pubitemid 40396800)
29. Paternoster DM, Fantinato S, Stella A, Nanhornguè KN, Milani M, Plebani M, Nicolini U, Girolami A. C-reactive protein in hypertensive disorders in pregnancy. Clin Appl Thromb Hemost 2006;12:330-337. (Pubitemid 44400845)
30. Ertas IE, Kahyaoglu S, Yilmaz B, Ozel M, Sut N, Guven MA, Danisman N. Association of maternal serum high sensitive C-reactive protein level with body mass index and severity of pre-eclampsia at third trimester. J Obstet Gynaecol Res 2010;36:970-977.